1720: FAS^lpr Gene Dosage Differentiates Lymphoproliferative from Non-lymphoproliferative Autoimmunity – a Novel Mouse Model of Lupus

Ritu Bohat¹, Chunyu Xu¹, Xiaofang Liang¹, Yanping Chen¹, Ningbo Zheng¹, Roshni Jaffery¹, Ashley Guerrero¹, Nicholas Egan¹, John Hicks², Chandra mohan¹ and Weiyi Peng¹, ¹University of Houston, Houston, TX, ²Baylor College of Medicine, Houston, TX

Background/Purpose: Sle1 and FAS^lpr are two lupus susceptibility loci that lead to manifestations of systemic lupus erythematosus (SLE) by altering the FAS/FASL pathway and adaptive immunity. Although C57BL/6 (B6) mice bearing either of these genes display mild phenotypes, the epistatic interaction of Sle1 and FAS^lpr results in severe lupus, confirming that these two genes impact non-redundant, pathways. Here, we aim to evaluate whether FAS^lpr exhibits gene dosage effects in determining cellular and serological phenotypes associated with lupus.

Methods: B6, B6.FAS^lpr/lpr (lpr^homo), B6.Sle1/Sle1 (sle1), B6.Sle1/Sle1.FAS^lpr/+ (sle1.lpr^het), and B6.Sle1/Sle1.FAS^lpr/lpr (sle1.lpr^homo) mice were bred and examined at three different ages: 2-3 month (mo), 4-8 mo, 10-12 mo. Serum levels of antinuclear antibody (ANA) and cytokines were determined by ELISA and Luminex, respectively. The cellular composition and function of immune cells in spleen and kidney tissues were characterized by flow cytometry. Urine protein level and pathology were used to evaluate renal damage.

Results: Sle1.lpr^homo mice exhibited prominent splenomegaly and lymphadenopathy, associated with early mortality (median lifespan = 4 mo). In contrast, sle1.lpr^het mice exhibited a lifespan comparable to sle1 mice (100% alive at 12 mo age), with no evidence of splenomegaly or lymphadenopathy till 12 mo of age. Compared to the sle1 and lpr controls, sle1.lpr^het mice exhibited significantly elevated serum IgG anti-dsDNA antibodies, from 4 mo of age (p< 0.05), with the phenotype being more prominent in females. Similar to the serological differences, sle1.lpr^het mice exhibited increased proteinuria compared to the single gene controls. Renal pathology assessment is in progress.

To elucidate the mechanistic basis for the observed differences, further cellular, and serological phenotyping was carried out. The percentages of immune subsets including CD4/CD8 T cells, B cells, monocytes, and NK cells in spleens from sle1.lpr^het mice at 4-8 mo were comparable with those in the single gene controls. However, when cultured ex-vivo, sle1.lpr^het T-cells had an increased propensity to differentiate into both Th1 and Th2 cells, compared to the single gene controls. In contrast, homozygous mutation of FAS^lpr led to reduced T-reg cells, with profound skewing to effector/memory T-cells, increased CD4:CD8 ratios, and Ki67+ proliferating cells, features associated with lymphoproliferative disease. Indeed homozygous absence of FAS was necessary to upregulate 24 out of 36 serum cytokines interrogated. In contrast, gene dose effects of FAS^lpr were noted in upregulating serum IL-1 alpha, IL-2 and IL-27.

Conclusion: In contrast to sle1.lpr^homo mice which exhibit profound lymphoproliferation and early mortality, sle1.lpr^het mice is a more faithful model of human SLE based on its serological and renal phenotypes, without the confounding effect of lymphoproliferation. Whereas the complete absence of FAS leads to impaired activation induced cell death, reduced levels of FAS may regulate T-cell differentiation and production of key cytokines implicated in autoimmunity, including IL-1 alpha, IL-2 and IL-27.

Disclosures: R. Bohat, None; C. Xu, None; X. Liang, None; Y. Chen, None; N. Zheng, None; R. Jaffery, None; A. Guerrero, None; N. Egan, None; J. Hicks, None; C. mohan, None; W. Peng, Fresh Wind Biotechnologie.